Peijia Medical is a globally service provider of innovative medical products and solutions. Focusing on the innovation, R&D and production of high-end medical devices for structural heart and cerebrovascular disease intervention. It covers the entire product pipeline for the aortic valve, mitral valve and tricuspid valve, as well as surgical instruments and accessories, and diseases related to hemorrhage, ischemia and pathways in the field of cerebrovascular intervention. It has built China’s relatively comprehensive product portfolio and solutions set in the field of structural heart disease and cerebrovascular intervention.
Peijia Medical was established in 2012, is headquartered in Suzhou, Jiangsu Province, China, and was listed on the Main Board of the Hong Kong Stock Exchange in May 2020. Stock Code 9996.HK.